Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289679 | 0.88 | SLC6A2 (0.58) | OPRK1OPRD1OPRM1REN | |
| SCHEMBL34461869 | 0.88 | OPRD1 (0.60) | OPRD1OPRM1 | |
| SCHEMBL2195454 | 0.87 | OPRD1 (0.55) | OPRK1OPRD1REN | |
| SCHEMBL30259604 | 0.87 | REN (0.53) | OPRK1OPRD1OPRM1REN | |
| Thymoctonan SCHEMBL15532000 | 0.86 | REN (0.52) | OPRK1OPRD1OPRM1REN | |
| Thymoctonan SCHEMBL1230532 | 0.86 | REN (0.52) | OPRK1OPRD1OPRM1REN | |
| SCHEMBL31694408 | 0.86 | F2 (0.58) | OPRK1OPRD1OPRM1 | |
| SCHEMBL29666108 | 0.86 | APLNR (0.47) | OPRD1REN | |
| SCHEMBL29679540 | 0.85 | OPRD1 (0.57) | OPRK1OPRD1OPRM1 | |
| SCHEMBL17456231 | 0.85 | REN (0.51) | OPRK1OPRD1OPRM1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4441070-A1 | MODIFIED AMATOXINS AND USES THEREOF | The University of British Columbia (CA) | 2024-10-09 | — | — | EP | claimed |
| US-20240082416-A1 | AMATOXIN ANALOGS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-03-14 | — | — | US | claimed |
| WO-2023097407-A1 | MODIFIED AMATOXINS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-06-08 | — | — | WO | claimed |
| WO-2025099489-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD20 AND CD22 AND USES THEREOF | LIGACHEM BIOSCIENCES INC. (KR) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025073057-A1 | METHODS FOR PREPARING SULFILIMINES AND SULFOXIMINES FROM THIOETHERS USING O-(DIPHENYLPHOSPHINYL)HYDROXYL AMINE (DPPH), AND AMATOXIN ANALOGS PREPARED FROM SUCH METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024243706-A1 | AMATOXIN ANALOGS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-12-05 | — | — | WO | disclosed |
| EP-4441070-A1 | MODIFIED AMATOXINS AND USES THEREOF | The University of British Columbia (CA) | 2024-10-09 | — | — | EP | disclosed |
| US-20240108739-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | PHI PHARMA SA (CH) | 2024-04-04 | — | — | US | disclosed |
| US-20240082416-A1 | AMATOXIN ANALOGS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-03-14 | — | — | US | disclosed |
| EP-4262879-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | Phi Pharma SA (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-4259643-A1 | AMATOXIN ANALOGS AND USES THEREOF | The University of British Columbia (CA) | 2023-10-18 | — | — | EP | disclosed |
| CN-116648266-A | Oligomeric compounds that specifically bind to proteoglycans | 菲药物股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023097407-A1 | MODIFIED AMATOXINS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022129627-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | PHI PHARMA SA (CH) | 2022-06-23 | — | — | WO | disclosed |
| EP-4015004-A1 | PROTEOGLYCAN SPECIFIC BRANCHED PEPTIDES | Phi Pharma SA (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022120476-A1 | AMATOXIN ANALOGS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108739-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | CD44, CSGALNACT1, LGALS3BP | OPRK1 3140/4885OPRD1 2731/4885OPRM1 2320/4885 |
| US-20240082416-A1 | AMATOXIN ANALOGS AND USES THEREOF | VIP, MTX1, APLNR | OPRK1 1437/4885OPRD1 1751/4885OPRM1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.